Literature DB >> 25303310

α-Hemolysin activity of methicillin-susceptible Staphylococcus aureus predicts ventilator-associated pneumonia.

Lukas Stulik1, Stefan Malafa, Jana Hudcova, Harald Rouha, Bence Z Henics, Donald E Craven, Agnes M Sonnevend, Eszter Nagy.   

Abstract

RATIONALE: Colonization of lower airways by Staphylococcus aureus is a risk factor for the development of ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). However, little is known about the virulence factors of methicillin-sensitive and -resistant S. aureus (MSSA and MRSA) that may influence host colonization and progression to VAT and VAP.
OBJECTIVES: We evaluated MRSA and MSSA endotracheal aspirates (ETA) for genotype and α-hemolysin activity in relation to the development of VAT and VAP.
METHODS: Serial S. aureus ETA isolates from ventilated patients were analyzed for methicillin resistance, molecular type by Multi-Locus Sequence Typing and spa-typing, and α-hemolysin activity by semiquantitative analysis of hemolysis on sheep blood agar and quantitative measurement of cytolysis of human lung epithelial cells. The virulence of selected strains was assessed in mice by intranasal challenge.
MEASUREMENTS AND MAIN RESULTS: We detected S. aureus from ETA samples in a quarter of the 231 ventilated patients analyzed; one-third of them developed VAP. VAP patients (n = 15) were mainly infected by MSSA strains (87%), whereas colonized individuals (n = 18) not progressing to disease mainly carried MRSA strains (68%). MSSA isolates from colonized or VAT patients exhibited significantly lower α-hemolysin activity than those from VAP cases; however, no such relationship was found with MRSA strains. α-Hemolysin activity of S. aureus isolates was predictive for virulence in mouse pneumonia model.
CONCLUSIONS: MSSA strains with strong blood agar hemolysis and high α-hemolysin activity are markers for VAP, but not VAT, and might be considered in differential diagnosis and initiation of therapy.

Entities:  

Keywords:  Staphylococcus aureus; biomarker; ventilator-associated pneumonia; α-hemolysin

Mesh:

Substances:

Year:  2014        PMID: 25303310     DOI: 10.1164/rccm.201406-1012OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  27 in total

1.  Disruption of staphylococcal aggregation protects against lethal lung injury.

Authors:  Jaime L Hook; Mohammad N Islam; Dane Parker; Alice S Prince; Sunita Bhattacharya; Jahar Bhattacharya
Journal:  J Clin Invest       Date:  2018-02-12       Impact factor: 14.808

2.  Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations.

Authors:  Yuling Wu; Xu Liu; Ahmad Akhgar; Jia J Li; Hoyin Mok; Bret R Sellman; Li Yu; Lorin K Roskos; Mark T Esser; Alexey Ruzin
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

3.  Targeting Alpha Toxin To Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.

Authors:  Binh An Diep; Jamese J Hilliard; Vien T M Le; Christine Tkaczyk; Hoan N Le; Vuvi G Tran; Renee L Rao; Etyene Castro Dip; Eliane P Pereira-Franchi; Paulyn Cha; Scott Jacobson; Rosemary Broome; Lily I Cheng; William Weiss; Laszlo Prokai; Vien Nguyen; C Ken Stover; Bret R Sellman
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin.

Authors:  Anna-Lena Neehus; Emmanuel Laplantine; Frederik Staels; Masato Ogishi; Yoann Seeleuthner; Franck Rapaport; Stéphanie Humblet-Baron; Adrian Liston; Laurent Abel; Bertrand Boisson; Jean-Laurent Casanova; András N Spaan; Keenan A Lacey; Erika Van Nieuwenhove; Maya Chrabieh; David Hum; Mélanie Migaud; Araksya Izmiryan; Lazaro Lorenzo; Tatiana Kochetkov; Dani A C Heesterbeek; Bart W Bardoel; Ashley L DuMont; Kerry Dobbs; Solenne Chardonnet; Søren Heissel; Timour Baslan; Peng Zhang; Rui Yang; Dusan Bogunovic; Herman F Wunderink; Pieter-Jan A Haas; Henrik Molina; Griet Van Buggenhout; Stanislas Lyonnet; Luigi D Notarangelo; Mikko R J Seppänen; Robert Weil; Gisela Seminario; Héctor Gomez-Tello; Carine Wouters; Mehrnaz Mesdaghi; Mohammad Shahrooei; Xavier Bossuyt; Erdal Sag; Rezan Topaloglu; Seza Ozen; Helen L Leavis; Maarten M J van Eijk; Liliana Bezrodnik; Lizbeth Blancas Galicia; Alain Hovnanian; Aude Nassif; Brigitte Bader-Meunier; Bénédicte Neven; Isabelle Meyts; Rik Schrijvers; Anne Puel; Jacinta Bustamante; Ivona Aksentijevich; Daniel L Kastner; Victor J Torres
Journal:  Science       Date:  2022-06-17       Impact factor: 63.714

5.  Improved Protection in a Rabbit Model of Community-Associated Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia upon Neutralization of Leukocidins in Addition to Alpha-Hemolysin.

Authors:  Binh An Diep; Vien T M Le; Zehra C Visram; Harald Rouha; Lukas Stulik; Etyene Castro Dip; Gábor Nagy; Eszter Nagy
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.

Authors:  David E Tabor; Li Yu; Hoyin Mok; Christine Tkaczyk; Bret R Sellman; Yuling Wu; Vaheh Oganesyan; Tim Slidel; Hasan Jafri; Michael McCarthy; Patricia Bradford; Mark T Esser
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

7.  S. aureus blocks efferocytosis of neutrophils by macrophages through the activity of its virulence factor alpha toxin.

Authors:  Taylor S Cohen; Omari Jones-Nelson; Meghan Hotz; Lily Cheng; Lloyd S Miller; JoAnn Suzich; C Kendall Stover; Bret R Sellman
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

Review 8.  Staphylococcus aureus Arsenal To Conquer the Lower Respiratory Tract.

Authors:  Mariane Pivard; Karen Moreau; François Vandenesch
Journal:  mSphere       Date:  2021-05-19       Impact factor: 4.389

9.  Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis.

Authors:  Jonathan Save; Yok-Ai Que; José M Entenza; Camille Kolenda; Frédéric Laurent; Grégory Resch
Journal:  J Am Heart Assoc       Date:  2022-01-19       Impact factor: 6.106

10.  Pre-emptive antibiotic therapy to reduce ventilator-associated pneumonia: "thinking outside the box".

Authors:  Donald E Craven; Jana Hudcova; Yuxiu Lei; Kathleen A Craven; Ahsan Waqas
Journal:  Crit Care       Date:  2016-09-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.